WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
FONR
FONAR CORP
$115.16M$102.42M$25.75M$12.16M$1.895.78%4.06%51.20%-8.83%2024-05-13
STRR
STAR EQUITY HOLDINGS INC
$14.18M$45.79M$26.87M$23.22M$1.61-19.88%-15.16%N/A34.19%2024-05-13
ICLR
ICON PLC
$25.24B$8.12B$1.55B$612.34M$7.464.89%25.62%20.32%4.59%2024-04-25
IDXX
IDEXX LABORATORIES INC
$41.36B$3.66B$1.22B$845.04M$10.178.72%10.59%25.25%18.57%2024-05-01
RVTY
REVVITY INC
$12.78B$2.75B$1.25B$693.09M$5.56-16.95%-0.20%23.28%20.93%2024-05-09
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$12.39B$4.13B$1.03B$474.62M$9.273.86%12.75%-3.13%14.45%2024-05-09
NEOG
NEOGEN CORP
$2.68B$929.24M$188.76M$1.57M$0.0228.93%17.63%-50.00%-49.27%
TMO
THERMO FISHER SCIENTIFIC INC
$215.53B$42.86B$11.06B$6.00B$15.52-4.58%11.96%-12.56%16.25%2024-04-24
QGEN
QIAGEN NV
$9.17B$1.97B$688.56M$341.30M$1.50-8.23%5.53%-19.35%11.61%2024-04-30
A
AGILENT TECHNOLOGIES INC
$41.24B$6.74B$1.69B$1.24B$4.22-2.81%6.19%-5.17%3.46%2024-05-21
SHC
SOTERA HEALTH CO
$3.19B$1.05B$406.83M$51.38M$0.184.54%7.06%N/AN/A2024-05-01
ENZ
ENZO BIOCHEM INC
$59.93M$12.81M$33.74M$32.57M$0.67N/A-32.08%N/AN/A2024-06-12
MEDP
MEDPACE HOLDINGS INC
$12.15B$1.89B$382.14M$282.81M$9.2029.17%21.76%21.53%35.02%2024-04-23
LH
LABORATORY CORP OF AMERICA HOLDINGS
$17.30B$12.16B$1.55B$418.00M$4.802.51%1.42%-65.84%-11.23%2024-04-25
CSTL
CASTLE BIOSCIENCES INC
$550.65M$219.79M-$45.02M-$57.47M-$2.1460.38%57.35%N/AN/A2024-05-01
DHR
DANAHER CORP
$177.49B$23.89B$8.04B$4.74B$6.44-10.33%6.98%-34.29%11.24%2024-04-23
TWST
TWIST BIOSCIENCE CORP
$1.77B$262.36M-$169.85M-$205.80M-$3.6121.58%51.75%N/AN/A2024-05-03
DGX
QUEST DIAGNOSTICS INC
$14.23B$9.25B$1.69B$854.00M$7.59-6.38%4.20%-6.30%7.09%2024-04-23
WAT
WATERS CORP
$19.10B$2.96B$1.00B$642.23M$10.87-0.52%4.09%-7.88%7.11%2024-05-07
MTD
METTLER TOLEDO INTERNATIONAL INC
$27.09B$3.79B$1.17B$788.78M$36.10-3.35%5.23%-6.93%12.17%2024-05-10
XGN
EXAGEN INC
$25.51M$52.55M-$18.21M-$23.69M-$1.3415.33%10.13%N/AN/A2024-05-13
SERA
SERA PROGNOSTICS INC
$313.23M$306.00k-$34.76M-$36.24M-$1.1614.18%N/AN/AN/A2024-05-08
IQV
IQVIA HOLDINGS INC
$42.51B$14.98B$3.26B$1.36B$7.393.98%7.55%26.98%42.22%2024-04-25
NTRA
NATERA INC
$11.41B$1.08B-$383.28M-$434.80M-$3.7831.99%33.26%N/AN/A2024-05-07
PRPO
PRECIPIO INC
$9.52M$15.20M-$4.32M-$5.85M-$4.5161.46%39.62%N/AN/A2024-05-15
EXAS
EXACT SCIENCES CORP
$12.95B$2.50B$52.20M-$204.15M-$1.1319.93%40.63%N/AN/A2024-05-08
PSNL
PERSONALIS INC
$64.39M$73.48M-$94.95M-$108.30M-$2.2512.97%14.23%N/AN/A2024-05-01
OLK
OLINK HOLDING AB (PUBL)
$2.84B$169.60M-$20.05M-$31.60M-$0.2521.27%N/AN/AN/A2024-05-09
DRIO
DARIOHEALTH CORP
$36.21M$20.35M-$54.38M-$63.51M-$1.93-26.41%22.45%N/AN/A2024-05-09
ACRS
ACLARIS THERAPEUTICS INC
$85.82M$31.25M-$87.99M-$88.48M-$1.275.03%38.41%N/AN/A2024-05-06
GH
GUARDANT HEALTH INC
$2.22B$563.95M-$433.31M-$479.45M-$4.2825.45%44.14%N/AN/A2024-05-07
DMTK
DERMTECH INC
$21.54M$15.30M-$95.04M-$100.89M-$3.095.36%44.33%N/AN/A2024-05-02
STIM
NEURONETICS INC
$128.55M$71.35M-$22.76M-$30.19M-$1.059.42%6.22%N/AN/A2024-05-07
NEO
NEOGENOMICS INC
$1.80B$591.64M-$8.37M-$87.97M-$0.7016.07%16.41%N/AN/A2024-04-30
BGLC
BIONEXUS GENE LAB CORP
$11.71M$10.34M-$2.87M-$3.09M-$0.22-8.80%N/AN/AN/A
FLGT
FULGENT GENETICS INC
$618.93M$289.21M-$134.12M-$167.83M-$5.63-53.27%68.41%N/AN/A2024-05-03
RDNT
RADNET INC
$3.32B$1.62B$265.49M$3.04M$0.0513.05%10.64%-73.68%-40.49%2024-05-07
BNR
BURNING ROCK BIOTECH LTD
$77.82M$74.64MN/A-$90.79M-$0.89-6.20%20.19%N/AN/A2024-05-28
APDN
APPLIED DNA SCIENCES INC
$6.43M$9.00M-$5.89M-$7.29M-$0.55-53.31%16.79%N/AN/A2024-05-09
PRE
PRENETICS GLOBAL LTD
$45.07M$21.74MN/A-$62.72M-$5.5865.17%18.68%N/AN/A
LAB
STANDARD BIOTOOLS INC
$809.43M$106.34M-$65.66M-$74.66M-$0.948.57%-1.20%N/AN/A2024-05-07
MDXH
MDXHEALTH SA
$6.27M$70.19M-$20.47M-$43.10M-$16.6089.43%N/AN/AN/A2024-05-08
BDSX
BIODESIX INC
$119.24M$49.09M-$37.10M-$52.15M-$0.6428.46%19.16%N/AN/A2024-05-09
CDNA
CAREDX INC
$441.67M$280.32M-$182.19M-$190.28M-$3.54-12.89%29.63%N/AN/A2024-05-08
CHEK
CHECK-CAP LTD
$13.22M$0.00-$19.08M-$17.62M-$3.02N/AN/AN/AN/A2024-05-06
ME
23ANDME HOLDING CO
$213.93M$247.99M-$490.64M-$521.97M-$1.11-19.40%N/AN/AN/A2024-05-26
ULS
UL SOLUTIONS INC
N/A$2.68B$519.00M$260.00M$1.306.27%N/A-11.56%N/A
XWEL
XWELL INC
$5.94M$30.26M-$30.04M-$34.61M-$8.18-61.07%-9.74%N/AN/A2024-05-13
PRPH
PROPHASE LABS INC
$117.65M$44.38M-$14.83M-$16.78M-$0.98-63.81%27.59%N/AN/A2024-05-09
AWH
ASPIRA WOMEN's HEALTH INC
$42.59M$9.15M-$16.50M-$16.69M-$1.8111.85%24.56%N/AN/A2024-05-09
NOTV
INOTIV INC
$153.71M$585.17M$59.57M-$33.21M-$1.30-0.18%81.64%N/AN/A2024-05-09
OPK
OPKO HEALTH INC
$857.30M$863.50M-$65.62M-$188.86M-$0.25-14.01%-2.70%N/AN/A2024-05-01
NDRA
ENDRA LIFE SCIENCES INC
$4.08M$0.00-$9.78M-$10.06M-$1.58N/A-100.00%N/AN/A2024-05-13
VNRX
VOLITIONRX LTD
$56.22M$775.30k-$33.68M-$35.32M-$0.50153.04%N/AN/AN/A2024-05-08
ISPC
ISPECIMEN INC
$2.06M$9.93M-$9.02M-$11.10M-$1.23-4.56%N/AN/AN/A2024-05-02
GENE
GENETIC TECHNOLOGIES LTD
$766.60k$5.55MN/A-$8.33M-$2.98-3.27%136.93%N/AN/A
MYGN
MYRIAD GENETICS INC
$1.76B$753.20M-$186.10M-$263.30M-$3.1811.03%-1.10%N/AN/A2024-05-01
BIAF
BIOAFFINITY TECHNOLOGIES INC
$27.17M$2.53M-$7.63M-$7.94M-$0.9152,627.44%N/AN/AN/A2024-05-13
PMD
PSYCHEMEDICS CORP
$15.82M$22.10M-$768.00k-$4.15M-$0.72-12.45%-12.33%N/AN/A2024-05-07
ILMN
ILLUMINA INC
$20.19B$4.50B-$608.00M-$1.16B-$7.34-1.75%6.21%N/AN/A2024-05-02
OCX
ONCOCYTE CORP
$22.39M-$2.36M-$54.87M-$58.14M-$9.48N/AN/AN/AN/A2024-05-09
MYNZ
MAINZ BIOMED NV
$20.53M$895.48k-$24.62M-$26.30M-$1.6269.00%N/AN/AN/A2024-05-13
TRIB
TRINITY BIOTECH PLC
$14.26M$56.83MN/A-$24.02MN/A-9.10%-10.15%N/AN/A
MMA
ALTA GLOBAL GROUP LTD
N/A$1.54M-$16.12M-$20.60M-$5.2663.35%N/AN/AN/A
CNTG
CENTOGENE NV
$15.32M$55.12M-$44.39M-$61.44M-$1.58N/AN/AN/AN/A2024-05-29
TTOO
T2 BIOSYSTEMS INC
$17.31M$7.19M-$42.53M-$50.08M-$19.19-67.75%-7.29%N/AN/A2024-05-21

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 8.75% over the past year, overperforming other diagnostic & research stocks by 12 percentage points.

2. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 5.71% over the past year, overperforming other diagnostic & research stocks by 9 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 17.32% from Idexx Laboratories's current stock price of $497.79.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 46.71% over the past year, overperforming other diagnostic & research stocks by 50 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 13.21% from Icon's current stock price of $306.00.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)


Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.19%, which is 2 percentage points higher than the diagnostic & research industry average of 1.37%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.24%, which is 1 percentage points higher than the diagnostic & research industry average of 1.37%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)


Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.4%, which is the same as the diagnostic & research industry average of 1.37%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -2.53% in the last day, and down -2.85% over the last week. Oncocyte was the among the top losers in the diagnostics & research industry, dropping -8.6% yesterday.

Oncocyte shares are trading higher after the company announced a transplant assay partnership agreement with Bio-Rad laboratories

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)


Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has dropped -0.56% in the past year. It has overperformed other stocks in the diagnostic & research industry by 3 percentage points.

2. Enzo Biochem (NYSE:ENZ)


Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -53.94% in the past year. It has underperformed other stocks in the diagnostic & research industry by -51 percentage points.

3. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 50 points higher than the diagnostic & research industry average of 21. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 8.75% in the past year. It has overperformed other stocks in the diagnostic & research industry by 12 percentage points.

Are diagnostic & research stocks a good buy now?

47.83% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 7.62% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 37.11x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.